Recruiting ADHD Studies in Savannah
Study to Evaluate NRCT-101SR in Pediatric Subjects with ADHD
To evaluate the efficacy and safety of NRCT-101SR compared to placebo in subjects 13-17 years of age with ADHD...
A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder
A combination therapy of NRCT-101 with NRCT-202 is being developed for patients with ADHD....
About ADHD Clinical Trials in Savannah
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity that interferes with functioning. It affects both children and adults. Treatment includes behavioral therapy, stimulant and non-stimulant medications, and educational support.
There are currently 2 adhd clinical trials recruiting participants in Savannah, GA. These studies are seeking a combined 220 participants. Research is being sponsored by Neurocentria, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.
ADHD Clinical Trials in Savannah — FAQ
Are there adhd clinical trials in Savannah?
Yes, there are 2 adhd clinical trials currently recruiting in Savannah, GA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Savannah?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Savannah research site will contact you about next steps.
Are clinical trials in Savannah free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Savannah studies also compensate for your time and travel.
What adhd treatments are being tested?
The 2 active trials in Savannah are testing new therapies including novel drugs, biologics, and treatment approaches for adhd.
Data updated March 2, 2026 from ClinicalTrials.gov